ERVIN GRAVES STRATEGY GROUP, LLC for EMERGENT BIOSOLUTIONS INC.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Disaster Planning/Emergencies DIS
Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone; State Opioid Response (SOR) Grants funding; H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021; Substance Abuse and Mental Health Block Grant (SABG) funding; H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; HR 3263 Outreach - DHS Medical Countermeasures Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES L ERVIN | — |
| COLBY MILLER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.